No doubt we should all be pleased that the shareholder class action brought against biotechnology company Sirtex over a 2016 profit downgrade has been settled.
Justice is done and the costs associated with running the final two weeks of the four-week Federal Court trial will not be foisted on the poor old taxpayer.
Loading...
James Thomson is senior Chanticleer columnist based in Melbourne. He was the Companies editor and editor of BRW Magazine. Connect with James on Twitter. Email James at j.thomson@afr.com
